{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-269536","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.552948+00:00","generated_at":"2026-05-16T23:56:32.539933+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Relay Therapeutics Q3 net loss $74.1M, cash $596.4M; appoints two directors","bullets":["Net loss $74.1M ($0.43 per share) vs $88.1M ($0.63) in Q3 2024.","Cash, cash equivalents and investments $596.4M at Sep 30, 2025; expected to fund operations into 2029.","R&D expenses $68.3M, down from $76.6M YoY on streamlining and cost avoidance.","Board appointed Lonnel Coats and Habib Dable, former biotech CEOs, effective Nov 4, 2025.","Continued Phase 3 ReDiscover-2 trial and Phase 1/2 ReInspire trial in vascular malformations."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-269536","json":"https://secwatch.observer/filing/0001193125-25-269536.json","markdown":"https://secwatch.observer/filing/0001193125-25-269536.md","text":"https://secwatch.observer/filing/0001193125-25-269536.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000119312525269536/0001193125-25-269536-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000119312525269536/rlay-20251104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:56:32.539933+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}